Sulopenem (IV to oral)
Complicated Urinary Tract Infection (cUTI), including acute pyelonephritis
Key Facts
About Iterum Therapeutics
Iterum Therapeutics is dedicated to addressing the critical public health crisis of antimicrobial resistance by developing next-generation antibiotics. Its primary candidate, sulopenem, is designed to treat resistant urinary tract infections (UTIs) and intra-abdominal infections where current oral options are failing. Despite facing significant setbacks, including a Complete Response Letter from the FDA for its NDA, the company continues to seek pathways to bring sulopenem to patients. Iterum operates as a lean, publicly traded entity (NASDAQ: ITRM) strategically headquartered in Ireland.
View full company profileAbout Iterum Therapeutics
Iterum Therapeutics is dedicated to addressing the critical public health crisis of antimicrobial resistance by developing next-generation antibiotics. Its primary candidate, sulopenem, is designed to treat resistant urinary tract infections (UTIs) and intra-abdominal infections where current oral options are failing. Despite facing significant setbacks, including a Complete Response Letter from the FDA for its NDA, the company continues to seek pathways to bring sulopenem to patients. Iterum operates as a lean, publicly traded entity (NASDAQ: ITRM) strategically headquartered in Ireland.
View full company profile